

Revenue guarantee models to secure availability of antibiotics – national approaches and the international context

Dr Chantal Morel, KPM Center for Public Management

RTA Swiss Round Table on Antibiotics Members Event

4 November 2024, Zürich

Where are we after 16 years of analyzing incentives in this space...



Critical attributes to fix the market:

- Delinked
- Credible
- Magnitude in line with value
- Magnitude in line prices of other drugs
- Pre-established
- Medium-to-long-term commitment

Revenue guarantee models

1. Subscription “Netflix” model (UK scheme)

- EEPRU/NICE valuation methods
- Shifted to simplified scoring

2. Opt-in model (DRIVE AB)

- Caveat in name
- Dependence on HERA top-up to be credible

3. Swedish model

- Sums intended to maintain some stocks in-country

Impact will depend on design

UK Subscription model  Novel antibiotics

- EEPRU/NICE valuation methods
- Shifted to simplified scoring

Swedish model  Access to existing antibiotics

- Sums intended to maintain minimal stocks of antibiotics already on the market

Moving forward in Switzerland...

- We will only get what we pay for
- Joining forces amplifies the market signal
- Joining forces amplifies leverage surrounding access-related demands
- Variety in incentive models increases administrative waste
- Design can combine innovation and access to older, generic drugs
- Don't be afraid of major changes in health technology assessment – Instead remove the need for it!
- Timing for implementation is important given the scientific challenges ahead
- Leadership needed from RTA, FOPH, clinicians, small and large pharma
- Let's learn from the last 16 years... please